Key result
Metformin pretreatment and systemic administration significantly increased the survival of transplanted cardiosphere-derived cells in post-myocardial infarction mouse hearts compared to cells without metformin.
Why the study?
Does metformin pretreatment improve the survival of transplanted cardiosphere-derived cells and enhance their therapeutic effect against myocardial infarction in a mouse model?
Does metformin pretreatment improve the survival of transplanted cardiosphere-derived cells and enhance their therapeutic effect against myocardial infarction in a mouse model?
Absolute Event Rate: 2.46% vs 1.08%
p-value: p=<0.05
Metformin pretreatment improves the survival of transplanted cardiosphere-derived cells via an AMPK-eNOS-dependent mechanism, enhancing their therapeutic efficacy in a mouse model of myocardial infarction.
Metformin-pretreated CDCs may enhance post-MI outcomes in mice; hypothesis-generating and leaves open human translation.
BACKGROUND: Transplantation of cardiosphere-derived cells (CDCs) has been shown to exert a therapeutic effect in patients with myocardial infarction (MI). However, poor survival of transplanted CDCs limits their beneficial effect. Metformin (MET) activates AMP-activated protein kinase (AMPK) which is associated with cell survival. The aim of this study is to determine whether MET improves CDC survival in the transplantation microenvironment and enhances the therapeutic effect of CDC transplantation against MI. METHODS: CDCs were isolated and expanded from transgenic β-actin-GFP mice. CDCs were pretreated with MET and intramyocardially injected into wild-type C57 mouse heart with MI injury. The survival of CDCs was quantified, and the infarct size and cardiac function of treated hearts were evaluated. RESULTS: CDC transplantation modestly reduced infarct size and improved cardiac function in the post-MI heart, which was further improved by MET treatment. MET pretreatment significantly increased the survival of CDCs transplanted into the myocardium. MET also reduced CDC apoptosis induced by oxidative stress in vitro. The anti-apoptotic effect of MET was blocked by the AMPK inhibitor compound C. MET increased AMPK phosphorylation and upregulated endothelial nitric oxide synthase (eNOS) in CDCs under oxidative stress, which might be associated with the anti-apoptotic effect of MET. CONCLUSIONS: MET improves the survival of transplanted CDCs in the myocardium, thereby enhancing their therapeutic effect against MI injury. The pro-survival function of MET on CDCs might be associated with an AMPK-eNOS-dependent mechanism.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2017) studied Myocardial infarction. Metformin vs. Vehicle/PBS or CDC alone was evaluated on CDC survival rate at 24 hours post-transplantation (p=<0.05). Metformin pretreatment and systemic administration significantly increased the survival of transplanted cardiosphere-derived cells in post-myocardial infarction mouse hearts compared to cells without metformin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: